HOLTUG LARS sold 236 Ascendis Pharma A/S shares at $264.13 each on Sep. 2, 2026, and held 4,000 shares afterward. The transaction gives investors a precise view of the insider’s reported post-sale position, while SEC code S identifies how the transaction was classified.
Key Highlights
- The transaction took place on Sep. 2, 2026.
- HOLTUG LARS held 4,000 Ascendis Pharma A/S shares after the sale.
- The transaction was recorded under SEC code S.
HOLTUG LARS sold 236 shares of Ascendis Pharma A/S at $264.13 per share. HOLTUG LARS is identified as an insider of Ascendis Pharma A/S.
Sep. 2 Transaction Leaves 4,000-Share Position
The transaction occurred on Sep. 2, 2026. Its SEC transaction code was S. The reported ownership position after the sale stood at 4,000 shares.
FAQs
Q: How many Ascendis Pharma shares did Holtug Lars sell?
A: HOLTUG LARS sold 236 shares of Ascendis Pharma A/S at $264.13 per share. The transaction occurred on Sep. 2, 2026.
Q: How many shares did Holtug Lars own after the insider transaction?
A: The reported post-transaction holding was 4,000 shares of Ascendis Pharma A/S. The transaction was classified under SEC code S for the transaction.
Q: What does the Holtug Lars insider sale mean for Ascendis Pharma investors?
A: The filing reports that HOLTUG LARS sold 236 shares and owned 4,000 shares afterward. It provides the transaction date, price, and SEC code S, but does not state a reason or expected effect.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.